BioPlus Acquisition Corp. (BIOS) Research
Currently, BioPlus Acquisition Corp. possesses no major active business operations. Its express mandate is to pursue and complete a strategic combination, which may take the form of a merger, share exchange, asset purchase, stock acquisition, reorganization, or similar transaction. This targeted consolidation is specifically aimed at one or more entities within the vibrant life sciences industry. The corporation was formally established in 2021 and maintains its principal executive offices in New York, New York.
Market snapshot
- Symbol
- BIOS
- Price
- $10.80
- Day change
- -0.05%
- Market cap
- $209.1M
- P/E ratio
- 1249.89x
- 52-week range
- 10.12-11.68
- Sector
- Financial Services
- Industry
- Shell Companies
Peer companies
Recent insider activity
- BioPlus Sponsor LLC — C-Conversion (5749999 shares) on 2023-06-05
- BioPlus Sponsor LLC — C-Conversion (5749999 shares) on 2023-06-05
- BioPlus Sponsor LLC — J-Other (380000 shares) on 2021-12-07
- BioPlus Sponsor LLC — J-Other (0 shares) on 2021-12-07
- BioPlus Sponsor LLC — trade (5175000 shares) on 2021-12-02
Open BioPlus Acquisition Corp. (BIOS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.